Zobrazeno 1 - 10
of 132
pro vyhledávání: '"Grant Prentice"'
Autor:
Moreno-Bost, Amberly, Szmania, Susann, Stone, Katie, Garg, Tarun, Hoerring, Antje, Szymonifka, Jackie, Shaughnessy, John, Jr., Barlogie, Bart, Grant Prentice, H., van Rhee, Frits
Publikováno v:
In Cytotherapy May 2011 13(5):618-628
Autor:
Sandra Korman, Wael Saber, Bijan Nejadnik, Paul G. Richardson, Christopher Strouse, Robin Hume, Mary M. Horowitz, Grant Prentice
Publikováno v:
Biology of Blood and Marrow Transplantation. 22:1306-1312
Veno-occlusive disease (VOD) is an early and serious complication of hematopoietic cell transplantation (HCT) that is associated with inferior survival, particularly when it is complicated by multiorgan failure (severe VOD). We evaluated the efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ca681f208f973080e6b3b424eedb102
https://doi.org/10.1016/j.bbmt.2016.04.011
https://doi.org/10.1016/j.bbmt.2016.04.011
Autor:
Hillard M. Lazarus, Georgina Buck, Susan M. Richards, Mark R. Litzow, R Chopra, Martin S. Tallman, Jacob M. Rowe, Jill Durrant, Peter H. Wiernik, Ian M. Franklin, Anthony H. Goldstone, H. Grant Prentice, Niculae Ciobanu, Alan Kenneth Burnett
The international acute lymphoblastic leukemia (ALL) study was designed to prospectively define the optimal therapy for adults 60 years of age or younger with newly diagnosed ALL. All patients received identical induction therapy, and 91% achieved co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0c381cd355b28e2acaa436742d03106
https://ora.ox.ac.uk/objects/uuid:971d5bfc-5a3a-4ea9-a4f4-e97b444243e1
https://ora.ox.ac.uk/objects/uuid:971d5bfc-5a3a-4ea9-a4f4-e97b444243e1
Autor:
H. Grant Prentice, Bart Barlogie, Antje Hoerring, Jackie Szymonifka, John D. Shaughnessy, Frits van Rhee, Amberly Moreno-Bost, Katie L. Stone, Tarun K. Garg, Susann Szmania
Publikováno v:
Cytotherapy. 13:618-628
Immunotherapy targeting MAGE-A3 in multiple myeloma (MM) could eradicate highly aggressive and proliferative clonal cell populations responsible for relapse. However, expression of many cancer-testis antigens, including MAGE-A3, can be heterogeneous,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30a3d55d06f38a0310346beeab43e0e1
https://doi.org/10.3109/14653249.2010.529893
https://doi.org/10.3109/14653249.2010.529893
Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis
Autor:
Vincent C. Emery, Andrew K. Burroughs, Paul Sweny, Alethea Cope, Paul D. Griffiths, Dehila Gor, E. Frances Bowen, Roland R. Regoes, Sebastian Bonhoeffer, Margaret A. Johnson, H. Grant Prentice, Aycan F. Hassan-Walker
Publikováno v:
Proceedings of the Royal Society B: Biological Sciences. 273:1961-1967
Human cytomegalovirus can cause a diverse range of diseases in different immunocompromised hosts. The pathogenic mechanisms underlying these diseases have not been fully elucidated, though the maximal viral load during infection is strongly correlate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31b730609c205e76c3d42ab05f4b4275
https://doi.org/10.1098/rspb.2006.3506
https://doi.org/10.1098/rspb.2006.3506
Splenectomy for Severe Autoimmune Cytopenias after Allogeneic Stem Cell Transplantation: Case Report
Publikováno v:
International Journal of Hematology. 82:75-78
Autoimmune cytopenias are rare but serious complications after hematopoietic stem cell transplantation (HSCT). We performed splenectomy in 2 patients who had severe autoimmune cytopenias after allogeneic HSCT (allo-HSCT) that were resistant to immuno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49397271d1e535d575fd45cb886e9ce7
https://doi.org/10.1532/ijh97.e0430
https://doi.org/10.1532/ijh97.e0430
Autor:
Anna Maria Geretti, Vanessa S. Brown, E. Hainsworth, Michael Potter, Sarah Grace, Geraldine Amooty, Grant Prentice, Vincent C. Emery, Paul D. Griffiths, Sylvester Okwuadi, G. Nebbia, F M Mattes, Paul Sweny, Andrew K. Burroughs, Aycan F. Hassan Walker, Caroline A. Sabin
Publikováno v:
The Journal of Infectious Diseases. 189:1355-1361
Forty-eight patients who provided 2 consecutive blood samples that tested positive for cytomegalovirus DNA by polymerase chain reaction (PCR) were randomized to receive either full-dose ganciclovir ( 5 mg/kg intravenously [iv] twice daily) or half-do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8a341aaa427e9ac2d5cd0c3767d2c73
https://doi.org/10.1086/383040
https://doi.org/10.1086/383040
Autor:
Cliona M. Rooney, M. Helen Huls, Malcolm K. Brenner, Robert H. Anderson, H. Grant Prentice, Catherine M. Bollard, Stephane Vigouroux, Helen E. Heslop, Hans-Joachim Wagner
Publikováno v:
Cancer Gene Therapy. 11:81-91
Adoptive immunotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T cells (CTL) is effective for the prophylaxis and treatment of EBV-induced lymphoma in hematopoietic stem cell recipients. However, in EBV-positive Hodgkin's disease (HD) the ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9732c63296ab61d1c645d2f9b93d321
https://doi.org/10.1038/sj.cgt.7700664
https://doi.org/10.1038/sj.cgt.7700664
Autor:
Michael N. Potter, Peter Rankin, A. Victor Hoffbrand, Atul Mehta, Andres Virchis, H. Grant Prentice, Mickey Koh
Publikováno v:
British Journal of Haematology. 124:26-32
The combination of fludarabine (FDR), high dose cytarabine and granulocyte colony stimulating factor (FLAG) with or without idarubicin (Ida) was used in the treatment of poor risk acute leukaemia or myelodysplastic syndrome (MDS) in a single centre e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7c2e83c03fe47d9d1ee44af2e6c5ce9
https://doi.org/10.1046/j.1365-2141.2003.04728.x
https://doi.org/10.1046/j.1365-2141.2003.04728.x
Publikováno v:
Journal of Virological Methods. 114:1-10
Recombinant adeno-associated virus type 2 (rAAV) has promise for use as a gene therapy vector. Potential problems in the production of rAAV stocks are both the limited amount of recombinant virus that is produced by traditional methods and the possib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74b7791e6b3e7a2ddfec2f8110bbf53c
https://doi.org/10.1016/j.jviromet.2003.08.001
https://doi.org/10.1016/j.jviromet.2003.08.001